# Study to Compare the Efficacy and Safety of F-627 and GRAN®

Source: https://onco.cc/trials/nct04174599/  
OnCo record `nct04174599` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Efbemalenograstim alfa and Filgrastim in Breast cancer, run by EVIVE Biotechnology, completed.

## Summary

Study to Compare the Efficacy and Safety of F-627 and GRAN® is a phase 3 interventional study registered as NCT04174599 by EVIVE Biotechnology, with 242 participants recorded, started 2018-04-12 and reaching its primary completion in 2019-01-24. Interventions recorded: F-627, GRAN®. Conditions recorded: Breast Cancer, Neutropenia.

Linked to the drug Efbemalenograstim alfa because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04174599
- Phase: 3
- Setting: A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of F-627 and GRAN® in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia
- Sponsor: EVIVE Biotechnology
- Enrolled: 242

## Sources

- ClinicalTrials.gov NCT04174599: https://clinicaltrials.gov/study/NCT04174599

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Efbemalenograstim alfa](https://onco.cc/drugs/efbemalenograstim-alfa/), [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/)
- companies: [Evive Biotech](https://onco.cc/companies/evive-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct04174599.json